Pelthos Therapeutics Inc. Common Stock PTHS 深 滬
已收盤 12-12 16:00:00 美东时间
22.99
-0.950
-3.97%
華盛通- 最 高25.38
- 今 開25.38
- 成交量 2.29万股
- 最 低 22.75
- 昨 收 23.94
- 總市值 6993.79万
- 52周最高 54.29
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.62
- 委 比 0.00%
- 總股本 304.21万
- 歷史最高 60.00
- 量 比 1.07
- 振 幅 10.99%
- 歷史最低 4.50
- 每 手 1
- 風險率 8.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
12-04 09:38
HC Wainwright & Co. Initiates Coverage On Pelthos Therapeutics with Buy Rating, Announces Price Target of $60
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Buy rating and announces Price Target of $60.
12-03 20:06
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
11-26 10:07
Roth Capital Initiates Coverage On Pelthos Therapeutics with Buy Rating, Announces Price Target of $57
Roth Capital analyst Jonathan Aschoff initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Buy rating and announces Price Target of $57.
11-26 02:18
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Oppenheimer Reiterates Outperform on Pelthos Therapeutics, Raises Price Target to $57
Oppenheimer analyst Jeff Jones reiterates Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $50 to $57.
11-15 01:28
Pelthos Therapeutics Q3 EPS $(5.30) Misses $(0.55) Estimate, Sales $7.406M Beat $4.380M Estimate
Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(5.30) per share which missed the analyst consensus estimate of $(0.55) by 863.64 percent. The company reported quarterly sales of $7.406 million which beat
11-13 19:46
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch
Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings.
11-07 20:52
Pelthos Therapeutics Launches Zelsuvmi for Skin Condition
Pelthos Therapeutics ( ($PTHS) ) has shared an update. On October 14, 2025, Pel...
10-14 20:23
